Evidence map›Paper›PMID 41705749›Full record

ArticleJACC. CardioOncology2026

Atrial Fibrillation Following Autologous Stem Cell Transplantation in Multiple Myeloma: Incidence, Predictors, and Prognostic Impact.

Olayiwola Bolaji, Samantha Brown, Brian C Shaffer, Glenn Heller, Marie-Claude Beaulieu, James E Ip, Carol L Chen, Sergio Giralt, Ioanna Kosmidou, Heather J Landau and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. CardioOncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Olayiwola BolajiDepartment of Internal Medicine, Cardiology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Samantha BrownDepartment of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Brian C ShafferDepartment of Internal Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Department of Internal Medicine, Weill Cornell Medicine, New York, New York, USA.
Glenn HellerDepartment of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Marie-Claude BeaulieuDepartment of Internal Medicine, Cardiology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
James E IpDepartment of Internal Medicine, Weill Cornell Medicine, New York, New York, USA.
Carol L ChenDepartment of Internal Medicine, Cardiology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Department of Internal Medicine, Weill Cornell Medicine, New York, New York, USA.
Sergio GiraltDepartment of Internal Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Department of Internal Medicine, Weill Cornell Medicine, New York, New York, USA.
Ioanna KosmidouDepartment of Internal Medicine, Cardiology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Department of Internal Medicine, Weill Cornell Medicine, New York, New York, USA.
Heather J LandauDepartment of Internal Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Department of Internal Medicine, Weill Cornell Medicine, New York, New York, USA.
Usmani SaadDepartment of Internal Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Department of Internal Medicine, Weill Cornell Medicine, New York, New York, USA.
Michael ScordoDepartment of Internal Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Department of Internal Medicine, Weill Cornell Medicine, New York, New York, USA.
Gunjan ShahDepartment of Internal Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Department of Internal Medicine, Weill Cornell Medicine, New York, New York, USA.
Roni ShouvalDepartment of Internal Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Department of Internal Medicine, Weill Cornell Medicine, New York, New York, USA.
Anthony F YuDepartment of Internal Medicine, Cardiology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Department of Internal Medicine, Weill Cornell Medicine, New York, New York, USA.
Jennifer E LiuDepartment of Internal Medicine, Cardiology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Department of Internal Medicine, Weill Cornell Medicine, New York, New York, USA. Electronic address: liuj1234@mskcc.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundAtrial fibrillation (AF) is a common and clinically significant complication in cancer patients, but data on its incidence and impact among multiple myeloma (MM) patients undergoing autologous stem cell transplantation (ASCT) remain limited.

objectivesThe aim of this study was to characterize the incidence, predictors, and prognostic implications of AF following ASCT in MM patients.

methodsA total of 801 MM patients who underwent ASCT between 2016 and 2022 were retrospectively analyzed. Pretransplantation evaluation included electrocardiography and echocardiography within 180 days of conditioning. Patients with AF at baseline were excluded. Post-transplantation AF was defined as electrocardiography-confirmed AF occurring after stem cell infusion.

resultsOver a median follow-up period of 36.2 months, 70 patients (8.7%) developed post-transplantation AF. The cumulative incidence was 5.5% at 90 days and 9.0% at 3 years, with a median onset of 13 days. Independent predictors included age >65 years (HR: 1.88; 95% CI: 1.16-3.07), prior paroxysmal AF (HR: 6.19; 95% CI: 3.63-10.5), and obesity (HR: 2.00; 95% CI: 1.10-3.63). Left atrial volume index >34 mL/m

conclusionsAF is a frequent and high-risk complication among MM patients undergoing ASCT. Routinely available clinical factors enable risk stratification, underscoring the importance of cardiovascular evaluation and vigilant post-transplantation monitoring in this vulnerable population.

Indexed as

arrhythmiaatrial fibrillationautologous stem cell transplantationbone marrow transplantationhematopoietic cell transplantationmultiple myelomasurvival

Identifiers

PMID41705749
PMCPMC12922618

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.